Please assess the completion status of the following clinical trial:

Trial Title: Bevacizumab for Primary Pterygium Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary pterygium~Exclusion Criteria:~* Patients with diabetes mellitus~* collagenopathies,~* previous ocular surgeries,~* pregnant or lactating patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- One subconjunctival injection (Type: EXPERIMENTAL): Autoconjunctival grafting and one subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery
- Two subconjuctival injections (Type: EXPERIMENTAL): Autoconjunctival grafting and subconjuntival bevacizumab injection (2.5mg/0.1ml) was applied after surgery, with another injection 15 days after surgery
- Conventional treatment (Type: ACTIVE_COMPARATOR): Autoconjunctival grafting without subconjuntival bevacizumab injection

Based on this trial design, predict the completion outcome and termination type (if applicable).